0KCS Stock Overview
A healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OPKO Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.49 |
| 52 Week High | US$1.74 |
| 52 Week Low | US$0.85 |
| Beta | 1.63 |
| 11 Month Change | -3.80% |
| 3 Month Change | 8.05% |
| 1 Year Change | 15.53% |
| 33 Year Change | -60.36% |
| 5 Year Change | n/a |
| Change since IPO | -69.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KCS | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -0.6% | -2.0% | -0.6% |
| 1Y | 15.5% | -14.4% | 6.6% |
Return vs Industry: 0KCS exceeded the UK Healthcare industry which returned -14.4% over the past year.
Return vs Market: 0KCS exceeded the UK Market which returned 6.6% over the past year.
Price Volatility
| 0KCS volatility | |
|---|---|
| 0KCS Average Weekly Movement | 6.8% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KCS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0KCS's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3,930 | Phil Frost | www.opko.com |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
OPKO Health, Inc. Fundamentals Summary
| 0KCS fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$243.10m |
| Revenue (TTM) | US$716.37m |
1.4x
P/S Ratio-4.2x
P/E RatioIs 0KCS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KCS income statement (TTM) | |
|---|---|
| Revenue | US$716.37m |
| Cost of Revenue | US$619.86m |
| Gross Profit | US$96.51m |
| Other Expenses | US$339.61m |
| Earnings | -US$243.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 13.47% |
| Net Profit Margin | -33.93% |
| Debt/Equity Ratio | 14.5% |
How did 0KCS perform over the long term?
See historical performance and comparison